Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

Drug–Drug, Drug–Food, Drug–Disease - NAPLEX

  1. A 70-year-old male (76 kg, 170 cm) is prescribed colchicine 0.6 mg PO twice daily for an acute gout flare. Medical history: gout, CKD stage 4, and hyperlipidemia. Current medications: atorvastatin 40 mg PO nightly, diltiazem ER 240 mg PO daily, and allopurinol 100 mg PO daily. Labs: SCr 2.6 mg/dL (ref 0.6–1.3), eGFR 24 mL/min/1.73 m², AST/ALT 30/28 U/L (ref 10–40), CK 110 U/L (ref 30–200). Allergies: none. Which medication needs adjustment due to the patient's condition?
    Answer: Avoid colchicine or use a reduced dose/alternative due to increased toxicity risk in severe CKD and with diltiazem This question evaluates drug-disease and drug-drug interaction management in a patient with severe renal impairment. The patient has CKD stage 4 (eGFR 24) and is taking diltiazem, a moderate CYP3A4 inhibitor. Colchicine is primarily eliminated renally and is also a CYP3A4 substrate, creating dual interaction risks. In severe CKD with concurrent CYP3A4 inhibitors, colchicine toxicity (diarrhea, myopathy, myelosuppression) is significantly increased. The FDA recommends avoiding colchicine or using reduced doses (0.3 mg daily or every other day) in this setting. Increasing colchicine (option A) would be dangerous, atorvastatin doesn't affect gout (option C), and allopurinol doesn't inactivate colchicine (option D) - though allopurinol should be avoided during acute flares. Clinical tip: In CKD patients requiring colchicine, always check for CYP3A4 inhibitors (diltiazem, verapamil, clarithromycin) and adjust colchicine dosing based on both renal function and drug interactions to prevent potentially fatal toxicity.
  2. A 27-year-old male (68 kg, 175 cm) is treated for latent TB with rifampin 600 mg PO daily. Current medications: buprenorphine/naloxone 8 mg/2 mg SL BID, escitalopram 10 mg PO daily. Medical history: OUD, depression. Labs: AST 18 U/L (10–40), ALT 20 U/L (7–56). Allergies: NKDA. What is the most important counseling point regarding interactions?
    Answer: Rifampin may reduce buprenorphine levels and precipitate withdrawal; monitor symptoms and coordinate dose adjustments with the prescriber This question addresses the pharmacokinetic interaction where rifampin, a strong CYP3A4 inducer, reduces buprenorphine levels, potentially precipitating opioid withdrawal. The patient's OUD on buprenorphine/naloxone and latent TB treatment highlight the risk of destabilizing maintenance therapy. Monitoring symptoms and coordinating buprenorphine dose adjustments with the prescriber is optimal to prevent withdrawal and relapse. Option B is incorrect as rifampin decreases, not increases, escitalopram levels, and stopping it risks depression worsening; Option C misapplies vitamin K avoidance, irrelevant to rifampin. Option D wrongly suggests grapefruit juice improves absorption, but it may inhibit metabolism unnecessarily; it confuses inhibitors. Pharmacists should anticipate 50% or more dose increases for substrates like buprenorphine during rifampin therapy. Collaborate with addiction specialists for monitoring and alternative TB regimens if possible.
  3. A 41-year-old female (58 kg, 164 cm) with asthma reports worsening wheeze after starting a new eye drop. Current medications: albuterol HFA 2 puffs q4–6h PRN, budesonide/formoterol 160/4.5 2 puffs BID, timolol ophthalmic 0.5% 1 drop OU BID (started 1 week ago). Medical history: asthma (persistent), glaucoma. Labs: none significant; SCr 0.8 mg/dL (0.6–1.1). Allergies: NKDA. Which medication needs adjustment due to the patient's condition?
    Answer: Timolol ophthalmic should be avoided due to systemic beta-blockade/bronchospasm risk; recommend alternative glaucoma therapy This question examines the disease-drug interaction where ophthalmic timolol, a nonselective beta-blocker, can cause systemic bronchospasm in asthma via beta-2 blockade absorption. The patient's persistent asthma and recent worsening wheeze after starting timolol highlight the exacerbation risk. Avoiding timolol and recommending alternative glaucoma therapies is optimal to prevent respiratory deterioration. Option B is incorrect as budesonide/formoterol does not interact to cause hypertension; Option C wrongly suggests discontinuing albuterol, which is essential. Option D misplaces need to switch albuterol, as it doesn't eliminate timolol's effect; it confuses isomers. Clinicians should prefer selective agents like betaxolol ophthalmic in asthma patients if beta-blockers are needed. Monitor symptoms and consider prostaglandin analogs as first-line for glaucoma in respiratory disease.
  4. A 57-year-old female (74 kg, 167 cm) with bipolar disorder presents with tremor, diarrhea, and confusion. Current medications: lithium carbonate 900 mg/day (300 mg PO TID), hydrochlorothiazide 25 mg PO daily, ibuprofen 600 mg PO TID PRN (using daily), sertraline 50 mg PO daily. Medical history: bipolar I disorder, HTN, OA. Labs: lithium level 1.9 mEq/L (0.6–1.2), SCr 1.4 mg/dL (0.6–1.1), Na 132 mEq/L (135–145). Allergies: NKDA. How should the pharmacist manage this interaction?
    Answer: Identify thiazide/NSAID-related lithium toxicity risk; advise immediate medical evaluation and contact prescriber to stop HCTZ/NSAID and adjust lithium This question assesses the pharmacokinetic interaction where thiazides like hydrochlorothiazide and NSAIDs like ibuprofen reduce lithium clearance, increasing levels and toxicity risk. The patient's symptoms of tremor, diarrhea, confusion, elevated lithium level, and hyponatremia indicate acute toxicity exacerbated by HTN and OA treatments. Identifying the risk and advising immediate evaluation with stopping HCTZ/NSAID and lithium adjustment is optimal for resolution. Option A is incorrect as increasing lithium would worsen toxicity; Option C misapplies grapefruit juice for tremor, irrelevant here. Option D wrongly suggests switching to fluoxetine reduces lithium, but it may increase it; it confuses SSRI effects. Pharmacists should monitor lithium levels closely with renal-impairing drugs and counsel on hydration. In bipolar patients, prefer lithium alternatives if chronic NSAIDs or diuretics are unavoidable.
  5. A 67-year-old female (64 kg, 160 cm) is prescribed ciprofloxacin 500 mg PO BID for 5 days for pyelonephritis. Current medications: theophylline ER 300 mg PO BID, albuterol inhaler PRN, prednisone 5 mg PO daily. Medical history: COPD, chronic theophylline use. Labs: SCr 1.1 mg/dL (0.6–1.1), AST/ALT WNL. Allergies: NKDA. Which drug interaction poses the greatest risk to this patient?
    Answer: Ciprofloxacin + theophylline increasing theophylline levels and toxicity; recommend alternative antibiotic or close level/toxicity monitoring This question evaluates the pharmacokinetic interaction between ciprofloxacin and theophylline, where ciprofloxacin inhibits CYP1A2, increasing theophylline levels and toxicity risk like seizures or arrhythmias. The patient's chronic theophylline use for COPD and pyelonephritis treatment heighten the potential for adverse effects. Recommending alternative antibiotics or close theophylline level monitoring is optimal to avoid toxicity. Option B is incorrect as ciprofloxacin and albuterol do not cause hypoglycemia; Option C wrongly claims loss of antibiotic effect with prednisone, and dairy hinders absorption. Option D misattributes hypertensive crisis to theophylline and prednisone; it confuses MAOIs. Pharmacists should adjust theophylline by 30-50% empirically or monitor levels within 24-48 hours. Counsel on toxicity signs like nausea and consider theophylline alternatives in COPD.
  6. A 47-year-old male (86 kg, 182 cm) with HIV presents for medication review after being prescribed fluticasone/salmeterol 250/50 mcg inhaled 1 puff twice daily for asthma. Current medications: darunavir/cobicistat 800/150 mg PO daily, emtricitabine/tenofovir alafenamide 200/25 mg PO daily, albuterol HFA 2 puffs q4–6h PRN, and cetirizine 10 mg PO daily. Medical history: asthma, HIV (viral load undetectable), and seasonal allergies. Labs: SCr 1.0 mg/dL (ref 0.6–1.3), AST/ALT 32/30 U/L (ref 10–40). Allergies: none. Which drug interaction poses the greatest risk to this patient?
    Answer: Fluticasone with cobicistat increasing systemic corticosteroid exposure and risk of adrenal suppression/Cushingoid effects This question evaluates recognition of a significant drug-drug interaction between inhaled corticosteroids and potent CYP3A4 inhibitors in HIV patients. The patient is taking darunavir/cobicistat, where cobicistat is a potent CYP3A4 inhibitor that can dramatically increase systemic exposure to fluticasone, even when inhaled. This can lead to iatrogenic Cushing's syndrome and adrenal suppression with serious consequences. Option B is incorrect as salmeterol and albuterol work synergistically, not antagonistically; option C is false as cetirizine and tenofovir don't interact; and option D is wrong as this combination doesn't cause hypoglycemia. The interaction is so significant that alternative corticosteroids (beclomethasone, budesonide at lower doses) are recommended. Clinical tip: In patients on protease inhibitors with pharmacokinetic enhancers (ritonavir, cobicistat), always screen for fluticasone-containing products (nasal sprays, inhalers) and recommend alternatives to prevent systemic corticosteroid effects.
  7. A 72-year-old male (90 kg, 175 cm) requests advice because he plans to start over-the-counter ibuprofen 600 mg PO three times daily for 1 week for back pain. Medical history: heart failure with reduced ejection fraction, hypertension, and osteoarthritis. Current medications: lisinopril 20 mg PO daily, furosemide 40 mg PO daily, spironolactone 25 mg PO daily, and carvedilol 12.5 mg PO twice daily. Labs: SCr 1.6 mg/dL (ref 0.6–1.3), K 5.2 mEq/L (ref 3.5–5.0), eGFR 42 mL/min/1.73 m², BNP 380 pg/mL (ref <100). Allergies: naproxen (rash). What is the best recommendation to minimize interaction risk?
    Answer: Recommend acetaminophen instead and avoid NSAIDs due to risk of AKI and hyperkalemia with ACE inhibitor/diuretics This question addresses the triple whammy interaction between NSAIDs, ACE inhibitors, and diuretics in a patient with heart failure and reduced kidney function. The patient has multiple risk factors: CKD (eGFR 42), hyperkalemia (K 5.2), heart failure, and concurrent spironolactone (potassium-sparing diuretic). NSAIDs reduce prostaglandin synthesis, which can precipitate acute kidney injury when combined with ACE inhibitors and diuretics, especially in volume-depleted or CKD patients. Acetaminophen is the safest analgesic option for this patient. Separating doses (option B) doesn't prevent the interaction, increasing furosemide (option C) could worsen dehydration and AKI risk, and temporarily switching antihypertensives (option D) is impractical and doesn't address the fundamental risk. Clinical tip: In patients with heart failure, CKD, or on ACE/ARB plus diuretic therapy, always recommend acetaminophen first-line for pain, with topical NSAIDs as second-line if systemic NSAIDs must be avoided.
  8. A 62-year-old male (88 kg, 177 cm) with chronic hepatitis C cirrhosis (Child-Pugh B) is prescribed zolpidem 10 mg PO at bedtime for insomnia. Current medications: lactulose 20 g PO TID, furosemide 20 mg PO daily, spironolactone 50 mg PO daily. Medical history: cirrhosis with prior hepatic encephalopathy, ascites. Labs: albumin 2.8 g/dL (3.5–5.0), total bilirubin 2.6 mg/dL (0.2–1.2), INR 1.6 (0.8–1.2), AST 78 U/L (10–40), ALT 52 U/L (7–56). Allergies: NKDA. Which medication needs adjustment due to the patient's condition?
    Answer: Zolpidem dose should be reduced/avoided due to increased sedation and encephalopathy risk in hepatic impairment This question evaluates the disease-drug interaction where zolpidem, a sedative metabolized by the liver, increases sedation and encephalopathy risk in hepatic impairment. The patient's Child-Pugh B cirrhosis with prior encephalopathy and ascites heighten vulnerability to CNS depression. Reducing or avoiding zolpidem dose is optimal to prevent worsening hepatic complications. Option B is incorrect as lactulose does not decrease zolpidem absorption; Option C wrongly suggests doubling spironolactone. Option D misattributes furosemide increasing zolpidem via CYP, unfounded; it confuses mechanisms. Clinicians should use lowest effective doses or non-sedating alternatives in cirrhosis. Assess for encephalopathy triggers and prioritize non-pharmacologic insomnia management.
  9. A 59-year-old male (78 kg, 170 cm) with gout calls the pharmacy because he started allopurinol 300 mg PO daily yesterday and now has a new prescription for azathioprine 100 mg PO daily from his gastroenterologist. Current medications: allopurinol 300 mg PO daily, prednisone 10 mg PO daily, mesalamine 2.4 g PO daily. Medical history: ulcerative colitis, gout. Labs: WBC 6.0 x103x10^3/µL (4–11), ANC 3.2 x103x10^3/µL (1.5–8), SCr 1.0 mg/dL (0.7–1.3), LFTs WNL. Allergies: NKDA. Which drug interaction poses the greatest risk to this patient?
    Answer: Allopurinol + azathioprine causing severe myelosuppression; avoid combination or drastically reduce azathioprine with close CBC monitoring This question evaluates the pharmacokinetic interaction between allopurinol and azathioprine, where allopurinol inhibits xanthine oxidase, increasing azathioprine's active metabolites and myelosuppression risk. The patient's ulcerative colitis and recent allopurinol initiation, with normal baseline CBC, underscore the need to prevent severe neutropenia. Avoiding the combination or reducing azathioprine drastically with CBC monitoring is optimal to mitigate toxicity. Option B is incorrect as mesalamine and prednisone do not cause adrenal crisis; Option C wrongly attributes serotonin syndrome, unrelated here. Option D misstates decreased uric acid control without evidence of separation benefit; it confuses mechanisms. Clinicians should reduce azathioprine to 25-33% of original dose with allopurinol and monitor CBC weekly initially. In IBD, consider alternative uricosurics like febuxostat to avoid this interaction.
  10. A 60-year-old female (74 kg, 165 cm) is picking up a new prescription for clarithromycin 500 mg PO twice daily for 10 days for community-acquired pneumonia. Medical history: hyperlipidemia, type 2 diabetes, and GERD. Current medications: simvastatin 40 mg PO nightly, metformin 1000 mg PO twice daily, omeprazole 20 mg PO daily, and aspirin 81 mg PO daily. Labs: AST/ALT 28/31 U/L (ref 10–40), SCr 0.9 mg/dL (ref 0.6–1.3), A1c 7.4% (ref 4.0–5.6). Allergies: none. Which drug interaction poses the greatest risk to this patient?
    Answer: Clarithromycin with simvastatin increasing risk of myopathy/rhabdomyolysis This question evaluates recognition of a contraindicated drug-drug interaction between clarithromycin and simvastatin. The patient is taking simvastatin 40 mg daily, which is metabolized by CYP3A4, and clarithromycin is a potent CYP3A4 inhibitor. This combination can increase simvastatin levels 10-fold, significantly increasing the risk of myopathy and potentially fatal rhabdomyolysis. Option B is incorrect as clarithromycin doesn't significantly affect metformin absorption; option C is wrong because clarithromycin doesn't reduce aspirin's antiplatelet effects; and option D is false as this combination doesn't cause hypertension. The FDA recommends avoiding simvastatin entirely during clarithromycin therapy. Clinical tip: When macrolides are needed in statin patients, azithromycin (no CYP3A4 inhibition) is preferred, or temporarily hold simvastatin/lovastatin during treatment.
  11. A 55-year-old female (68 kg, 160 cm) is starting a new prescription for linezolid 600 mg PO twice daily for 10 days for MRSA pneumonia. Medical history: major depressive disorder and hypertension. Current medications: sertraline 150 mg PO daily, trazodone 50 mg PO at bedtime PRN insomnia, amlodipine 10 mg PO daily, and hydrochlorothiazide 25 mg PO daily. Labs: SCr 0.8 mg/dL (ref 0.6–1.3), AST/ALT 20/18 U/L (ref 10–40), Na 138 mEq/L (ref 135–145). Allergies: penicillin (hives). How should the pharmacist manage this interaction?
    Answer: Recommend holding sertraline (and avoiding other serotonergic agents) during linezolid therapy and monitor for serotonin syndrome This question tests management of the serious drug-drug interaction between linezolid (a monoamine oxidase inhibitor) and serotonergic medications. The patient is taking sertraline 150 mg daily and trazodone PRN, both serotonergic agents that can cause serotonin syndrome when combined with linezolid. The FDA recommends avoiding this combination when possible, or holding serotonergic agents during linezolid therapy with close monitoring for serotonin syndrome symptoms (confusion, agitation, tremor, hyperthermia). Grapefruit juice (option A) is not a concern with linezolid, amlodipine doesn't interact significantly (option C), and separating doses (option D) doesn't prevent this pharmacodynamic interaction. Clinical tip: When linezolid is essential, document all serotonergic medications (including tramadol, dextromethorphan) and counsel patients on serotonin syndrome symptoms, with instructions to seek immediate care if they occur.
  12. A 72-year-old male (82 kg, 178 cm) presents to the pharmacy with new-onset muscle pain and dark urine 10 days after hospital discharge. Current medications: simvastatin 40 mg PO nightly, amlodipine 10 mg PO daily, metformin 1000 mg PO BID, aspirin 81 mg PO daily. Medical history: T2DM, HTN, hyperlipidemia. Labs today: SCr 1.6 mg/dL (0.7–1.3), eGFR 45 mL/min/1.73 m2m^2, AST 78 U/L (10–40), ALT 65 U/L (7–56), CK 2,800 U/L (30–200). Allergies: NKDA. Which drug interaction poses the greatest risk to this patient?
    Answer: Simvastatin + amlodipine increasing simvastatin exposure; reduce simvastatin dose or switch statin This question tests knowledge of the pharmacokinetic interaction between simvastatin and amlodipine, where amlodipine inhibits CYP3A4-mediated metabolism of simvastatin, leading to increased statin exposure and risk of myopathy or rhabdomyolysis. The patient's advanced age, reduced renal function (eGFR 45 mL/min/1.73 m²), and symptoms of muscle pain with dark urine and elevated CK highlight vulnerability to statin toxicity. Reducing simvastatin dose or switching to a statin less affected by amlodipine, such as pravastatin, is optimal for managing this interaction while maintaining lipid control. Option A is incorrect because metformin and aspirin do not interact to cause hypoglycemia, and stopping aspirin ignores its cardiovascular benefits; Option C is wrong as amlodipine does not reduce metformin absorption. Option D misrepresents the minor bleeding risk without warranting routine PPI addition; Option A also misunderstands the interaction direction. Clinicians should limit simvastatin to 20 mg daily with amlodipine per guidelines and monitor CK if symptoms arise. In elderly patients with CKD, consider alternative statins or dose adjustments to prevent adverse events.
  13. A 66-year-old male (84 kg, 173 cm) with COPD is prescribed propranolol 40 mg PO BID for essential tremor. Current medications: tiotropium inhaler 2 puffs daily, albuterol HFA 2 puffs q4–6h PRN, fluticasone/salmeterol 250/50 1 inhalation BID. Medical history: COPD (moderate), essential tremor, HTN. Labs: SpO2 93% on room air, SCr 1.0 mg/dL (0.7–1.3). Allergies: NKDA. Which medication needs adjustment due to the patient's condition?
    Answer: Propranolol should be avoided due to bronchospasm risk; recommend an alternative (e.g., primidone) or a cardioselective beta-blocker if needed This question examines the pharmacodynamic interaction of nonselective beta-blockers like propranolol with COPD, causing bronchospasm via beta-2 blockade. The patient's moderate COPD and use of bronchodilators like tiotropium and albuterol heighten the risk of asthma exacerbation. Avoiding propranolol and recommending alternatives like primidone or cardioselective beta-blockers is optimal to manage tremor without worsening respiratory status. Option B is incorrect as tiotropium does not antagonize propranolol; Option C wrongly suggests increasing albuterol, which doesn't offset the risk. Option D misattributes QT prolongation to fluticasone/salmeterol and propranolol, unfounded; it confuses adverse effects. Clinicians should select cardioselective agents like metoprolol for comorbidities in COPD patients. Monitor lung function and symptoms when initiating beta-blockers in respiratory disease.
  14. A 38-year-old female (75 kg, 170 cm) with recurrent UTIs is prescribed nitrofurantoin monohydrate/macrocrystals 100 mg PO BID for 5 days. Current medications: magnesium hydroxide 30 mL PO daily PRN constipation, omeprazole 20 mg PO daily. Medical history: constipation, GERD. Labs: SCr 1.6 mg/dL (0.6–1.1), eGFR 28 mL/min/1.73 m2m^2. Allergies: sulfa (hives). Which medication needs adjustment due to the patient's condition?
    Answer: Nitrofurantoin should be avoided due to low eGFR and reduced efficacy/increased toxicity risk; recommend alternative UTI agent based on culture/local guidance This question assesses the drug-disease interaction of nitrofurantoin in patients with renal impairment, focusing on efficacy and toxicity risks. The patient-specific factor is her reduced renal function with an eGFR of 28 mL/min/1.73 m², alongside recurrent urinary tract infections (UTIs), gastroesophageal reflux disease (GERD), and constipation managed with omeprazole and magnesium hydroxide. Choice A is optimal because nitrofurantoin is contraindicated in severe renal impairment (eGFR <30 mL/min/1.73 m²) due to inadequate urinary concentration leading to reduced efficacy and increased risk of systemic toxicity like peripheral neuropathy or pulmonary fibrosis, necessitating an alternative antibiotic based on culture and sensitivity. Choice B is incorrect as omeprazole does not inactivate nitrofurantoin; there is no such acid-related interaction requiring discontinuation. Choices C and D are wrong because magnesium hydroxide actually decreases nitrofurantoin absorption (not improves it), and increasing the dose would exacerbate toxicity risks without addressing the underlying renal clearance issue. A clinical tip is to always calculate eGFR before prescribing nitrofurantoin and avoid it if below 30 mL/min/1.73 m². For management in similar cases, consider agents like cephalexin or fosfomycin for UTIs in renally impaired patients, guided by local resistance patterns.
  15. A 48-year-old male (86 kg, 182 cm) with HIV presents for counseling on a new prescription for fluticasone nasal spray 2 sprays per nostril daily for allergic rhinitis. Current medications: darunavir/cobicistat 800 mg/150 mg PO daily, emtricitabine/tenofovir alafenamide 200 mg/25 mg PO daily. Medical history: HIV (undetectable viral load), allergic rhinitis. Labs: AST 24 U/L (10–40), ALT 26 U/L (7–56), SCr 1.0 mg/dL (0.7–1.3). Allergies: NKDA. Which drug interaction poses the greatest risk to this patient?
    Answer: Fluticasone + cobicistat increasing systemic steroid exposure; recommend alternative (e.g., beclomethasone) and monitor for Cushingoid effects This question tests the pharmacokinetic interaction where cobicistat, a CYP3A4 inhibitor in darunavir regimen, increases systemic exposure to inhaled/intranasal fluticasone, risking adrenal suppression. The patient's HIV therapy and allergic rhinitis highlight the potential for Cushingoid effects from amplified corticosteroid levels. Recommending alternatives like beclomethasone and monitoring for suppression is optimal to manage symptoms safely. Option B is incorrect as fluticasone and tenofovir do not cause nephrotoxicity warranting dose reduction; Option C wrongly attributes serotonin syndrome to darunavir and emtricitabine. Option D misstates decreased ART efficacy without separation benefit; it confuses directions. Pharmacists should avoid potent CYP3A4 inhibitors with most inhaled steroids, preferring non-substrates. Monitor for signs of hypercortisolism and consider systemic steroid alternatives if needed.
  16. A 52-year-old female (64 kg, 168 cm) is picking up a new prescription for ciprofloxacin 500 mg PO twice daily for 7 days for pyelonephritis. She reports taking sucralfate 1 g PO four times daily for an ulcer and a daily multivitamin with minerals. Medical history: peptic ulcer disease and recurrent UTIs. Current medications: sucralfate 1 g QID, multivitamin with iron and zinc 1 tablet daily, and famotidine 20 mg PO twice daily. Labs: SCr 0.7 mg/dL (ref 0.6–1.3), AST/ALT 18/16 U/L (ref 10–40). Allergies: none. What is the best recommendation to minimize interaction risk?
    Answer: Separate ciprofloxacin from sucralfate and mineral-containing products (e.g., iron/zinc) by at least 2 hours before or 6 hours after This question addresses chelation interactions between fluoroquinolones and polyvalent cations. The patient is taking sucralfate (aluminum-containing) and a multivitamin with minerals, both of which can chelate ciprofloxacin in the GI tract, reducing its bioavailability by up to 90%. Proper separation is critical: ciprofloxacin should be taken at least 2 hours before or 6 hours after these products to ensure adequate absorption for treating pyelonephritis. Taking them together (option A) would result in treatment failure, avoiding all dairy (option B) is excessive as small amounts don't significantly impact absorption, and doubling the dose (option D) is inappropriate and doesn't overcome chelation. Clinical tip: Create a detailed administration schedule for patients on fluoroquinolones with multiple interacting agents, emphasizing that inadequate separation can lead to treatment failure and resistance development.
  17. A 34-year-old female (60 kg, 162 cm) is starting a combined oral contraceptive (ethinyl estradiol/levonorgestrel 30 mcg/150 mcg 1 tab PO daily). Current medications: carbamazepine 400 mg PO BID, folic acid 1 mg PO daily. Medical history: focal epilepsy (well controlled). Labs: AST 22 U/L (10–40), ALT 24 U/L (7–56). Allergies: NKDA. What is the best recommendation to minimize interaction risk?
    Answer: Advise using a nonhormonal or long-acting method not affected by enzyme induction (e.g., copper IUD) or add reliable backup contraception This question tests the pharmacokinetic interaction where carbamazepine, a CYP3A4 inducer, reduces hormonal contraceptive levels, increasing failure risk. The patient's epilepsy treatment and need for reliable contraception highlight the potential for unintended pregnancy. Advising nonhormonal methods like copper IUD or backup contraception is optimal to ensure efficacy during enzyme induction. Option A is incorrect as carbamazepine decreases, not increases, contraceptive levels; Option C wrongly suggests high-fat meals overcome induction, ineffective. Option D misplaces dose reduction on carbamazepine, which could worsen seizure control; it misunderstands management. Pharmacists should recommend extended-cycle OCs or higher estrogen doses with inducers, extending backup for 28 days post-inducer. Counsel on signs of contraceptive failure and folic acid supplementation in epileptics.
  18. A 63-year-old female (66 kg, 158 cm) with chronic pain is prescribed tramadol 50 mg PO q6h PRN. Current medications: paroxetine 40 mg PO daily, trazodone 100 mg PO at bedtime, sumatriptan 50 mg PO PRN migraine (about twice weekly). Medical history: depression, insomnia, migraines. Labs: SCr 0.9 mg/dL (0.6–1.1), LFTs WNL. Allergies: codeine (nausea). Which drug interaction poses the greatest risk to this patient?
    Answer: Tramadol + serotonergic agents increasing serotonin syndrome risk; recommend alternative analgesic and counsel on symptoms This question examines the pharmacodynamic interaction of tramadol with serotonergic agents like paroxetine and trazodone, increasing serotonin syndrome risk via additive effects. The patient's use of sumatriptan, another serotonergic, and chronic pain with depression heighten vulnerability to symptoms like agitation and hyperthermia. Recommending alternative analgesics and counseling on syndrome symptoms is optimal to avoid this serious adverse event. Option B is incorrect as tramadol and paroxetine increase, not reduce, bleeding risk, and adding aspirin is unwarranted; Option C wrongly attributes hypertensive crisis, more typical of MAOIs. Option D misstates decreased migraine efficacy without need for separation; it confuses interactions. Clinicians should assess total serotonergic burden and prefer non-serotonergic options like acetaminophen/NSAIDs. Educate on early signs of serotonin syndrome and when to seek emergency care.
  19. A 66-year-old male (88 kg, 176 cm) with COPD is prescribed propranolol 40 mg PO twice daily for essential tremor. Medical history: COPD (on maintenance inhaler), essential tremor, and hypertension. Current medications: tiotropium 18 mcg inhaled daily, albuterol HFA 2 puffs q4–6h PRN, and lisinopril 10 mg PO daily. Labs: SCr 1.1 mg/dL (ref 0.6–1.3), K 4.3 mEq/L (ref 3.5–5.0). Allergies: none. Which medication needs adjustment due to the patient's condition?
    Answer: Recommend switching to a cardioselective beta-blocker (e.g., metoprolol) or alternative tremor therapy due to bronchospasm risk This question tests recognition of drug-disease interactions between nonselective beta-blockers and COPD. The patient has COPD and is prescribed propranolol, a nonselective beta-blocker that blocks both β1 and β2 receptors. Blocking β2 receptors in the lungs can cause bronchospasm and worsen COPD symptoms, potentially triggering acute exacerbations. The safest approach is switching to a cardioselective beta-blocker like metoprolol (primarily β1) or using alternative tremor therapy like primidone. Continuing propranolol (option A) risks respiratory compromise, discontinuing tiotropium (option C) would worsen COPD control without addressing the real issue, and increasing albuterol to scheduled dosing (option D) creates an antagonistic situation without solving the underlying problem. Clinical tip: In patients with reactive airway disease, always prefer cardioselective beta-blockers (metoprolol, atenolol, bisoprolol) when beta-blockade is necessary, and monitor for respiratory symptoms even with cardioselective agents at higher doses.
  20. A 73-year-old male (74 kg, 170 cm) stabilized on digoxin is prescribed verapamil ER 240 mg PO daily for rate control. Current medications: digoxin 0.125 mg PO daily, furosemide 40 mg PO daily, potassium chloride 20 mEq PO daily. Medical history: atrial fibrillation, HFrEF. Labs: digoxin level 0.9 ng/mL (0.5–0.9), K 4.0 mEq/L (3.5–5.0), SCr 1.3 mg/dL (0.7–1.3). Allergies: NKDA. Which drug interaction poses the greatest risk to this patient?
    Answer: Verapamil + digoxin increasing digoxin concentrations and bradycardia risk; consider digoxin dose reduction and monitor level/HR This question assesses the pharmacokinetic interaction between verapamil and digoxin, where verapamil inhibits P-gp, increasing digoxin levels and bradycardia risk. The patient's atrial fibrillation, HFrEF, and stable digoxin level heighten arrhythmia susceptibility with addition. Considering digoxin dose reduction and monitoring levels/HR is optimal to maintain therapeutic effects safely. Option B is incorrect as furosemide and potassium do not cause hypercalcemia; Option C wrongly claims reduced diuresis without evidence. Option D misstates decreased digoxin effect with potassium, actually beneficial; it confuses hypokalemia risks. Pharmacists should anticipate 30-50% digoxin increases with verapamil and check levels within 5-7 days. Monitor electrolytes and ECG in heart failure patients to prevent toxicity.

Start this quiz